Chief Operating Officer @ HelioGenetics (July 2013 - May 2020)
President and CSO @ Antyra (July 1999 - December 2013)
Chief Scientific Officer @ PanMetics (January 2012 - January 2013)
Vice-President @ GenQuest (January 1997 - December 1998)
Vice-President @ GenQuest (January 1997 - January 1998)
Director Immunology @ ImClone Systems (January 1987 - December 1997)
Director Immunology @ ImClone Systems (January 1987 - January 1997)
Researcher @ Sandoz Research Institute (January 1985 - January 1987)
Researcher @ Sandoz Research Institute (January 1985 - December 1987)
Director of Hybridoma Research @ (January 1983 - January 1985)
Director of Hybridoma Research @ (January 1983 - December 1985)
Researcher @ (January 1981 - January 1983)
Researcher @ (January 1981 - December 1983)
Member @ (January 1979 - January 1981)
Member @ (January 1979 - December 1981)
Neil Goldstein Education
The Wistar Institute
Postdoctoral Fellowship (Immunology)
1976-1979
Rutgers University
PhD (Microbiology)
1970-1975
City College of New York
BS (Biology)
1965-1969
Neil Goldstein Skills
Pharmaceuticals
Drug Discovery
Oncology
Diagnostics
Infectious Diseases
New Business Development
Business Strategy
Small Business
Medical Diagnostics
Validation
Monoclonal Antibodies
Biopharmaceuticals
Molecular Biology
Lifesciences
Cell
Clinical Trials
Immunology
Cancer
Clinical Development
Hardware Diagnostics
Vaccines
Biopesticide development
Management
Marketing
Pharmaceutical Industry
Neil Goldstein Summary
Neil Goldstein, based in Maplewood, NJ, US, is currently a Chief Scientific Officer at Skunkworx Bio. Neil Goldstein brings experience from previous roles at HelioGenetics, Antyra, PanMetics and GenQuest. Neil Goldstein holds a 1976 - 1979 Postdoctoral Fellowship in Immunology @ The Wistar Institute. With a robust skill set that includes Pharmaceuticals, Drug Discovery, Oncology, Diagnostics, Infectious Diseases and more. Neil Goldstein has 1 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Neil Goldstein?
Find contact details for 700 million professionals.